Events

Webinar on Safe & Sustainable by Design Framework (SSbD)
JUN
Thu
20
14:00 - 15:00

This was 8 months ago

Location

online

Programmes
ERC MSCA RI Digital, Industry & Space Climate, Energy, Mobility Agro-Food, Environment

NCP Flanders organises this webinar on the Safe and Sustainable by Design Framework: a guidance to scientists developing new chemicals or materials with the aim to make these safer and more sustainable.

It aims to

  • steer the innovation process towards the green and sustainable industrial transition
  • substitute or minimise the production and use of substances of concern, in line with, and beyond existing and upcoming regulatory obligations
  • minimise the impact on health, climate and the environment during sourcing, production, use and end-of-life of chemicals, materials and products

The Commission Recommendation from 8 December 2022 which announced the Framework reaches beyond HE projects, encouraging also national programmes to take up or industry to apply the framework when developing new chemicals or materials.

A representative of DG Research & Innovation from the European Commission will speak about the purpose of the framework, how it is to be used as part of a projects technical activities and the current status of the testing phase.

In a second part an expert from the Flemish Institute for Technological Research (VITO) will shed some light on the content of the SSbD framework.

There will be time for Q&A at the end of the presentations.

For registration (mandatory) click here.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.